Today $IMRX announced that IMM-1-104 has been granted Fast Track designation for the treatment of first-line pancreatic ductal adenocarcinoma (PDAC); providing the potential to accelerate IMM-1-104’s path to U.S. FDA submission for PDAC. buff.ly/3Wrsox9 #PancreaticCancer